Association of ATP-binding cassette transporter variants with the risk of Alzheimer's disease

Pharmacogenomics

Volumn 14, Issue 5, 2013, Pages 485-494

  Cascorbi, Ingolf ^a   Flüh, Charlotte ^a   Remmler, Cornelia ^a   Haenisch, Sierk ^a   Faltraco, Frank ^a,b   Grumbt, Maria ^c   Peters, Michele ^c   Brenn, Anja ^c   Thal, Dietmar Rudolf ^d   Warzok, Rolf Wolfgang ^c   Vogelgesang, Silke ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY OF ULM   (Germany)

Author keywords

amyloid; ABCA1; ABCA7; ABCC2; Alzheimer's; APOE; BRCP; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A4; BREAST CANCER RESISTANCE PROTEIN; DNA; MULTIDRUG RESISTANCE PROTEIN 1;

ABCA1 GENE; ABCA7 GENE; ABCB1 GENE; ABCC2 GENE; ABCG2 GENE; AGED; ALLELE; ALZHEIMER DISEASE; APOE4 GENE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATP-BINDING CASSETTE TRANSPORTERS; BRAIN; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX CHARACTERISTICS;

EID: 84875958482     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.18     Document Type: Article

References (52)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002 (Pubitemid 34790756)
2. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 118(1), 103-113 (2009
3. Cirrito JR, Deane R, Fagan AM et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-b deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115(11), 3285-3290 (2005 (Pubitemid 41567593)
4. Kuhnke D, Jedlitschky G, Grube M et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-b peptides - implications for the mechanisms of Ab clearance at the blood-brain barrier. Brain Pathol. 17(4), 347-353 (2007 (Pubitemid 47537591)
5. Lam FC, Liu R, Lu P et al. b-amyloid efflux mediated by P-glycoprotein. J. Neurochem. 76(4), 1121-1128 (2001
6. Vogelgesang S, Cascorbi I, Schroeder E et al. Deposition of Alzheimer's b-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12(7), 535-541 (2002 (Pubitemid 35177083)
7. Tai LM, Loughlin AJ, Male DK, Romero IA. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-b. J. Cereb. Blood Flow Metab. 29(6), 1079-1083 (2009
8. Xiong H, Callaghan D, Jones A et al. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Ab (1-40) peptides. J. Neurosci. 29(17), 5463-5475 (2009
9. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci. 25(8), 423-429 (2004 (Pubitemid 38981558)
10. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr. Top. Med. Chem. 9(2), 130-147 (2009
11. Rao VV, Dahlheimer JL, Bardgett ME et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl Acad. Sci. USA 96(7), 3900-3905 (1999 (Pubitemid 29169008)
12. Cascorbi I. ABC transporters in drug-refractory epilepsy: limited clinical significance of pharmacogenetics? Clin. Pharmacol. Ther. 87(1), 15-18 (2010
13. Kim WS, Guillemin GJ, Glaros EN, Lim CK, Garner B. Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport 17(9), 891-896 (2006 (Pubitemid 43869954)
14. Chan SL, Kim WS, Kwok JB et al. ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J. Neurochem. 106(2), 793-804 (2008
15. Jehle AW, Gardai SJ, Li S et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J. Cell Biol. 174(4), 547-556 (2006
16. Hollingworth P, Harold D, Sims R et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43(5), 429-435 (2011
17. Ufer M, Mosyagin I, Muhle H et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19(5), 353-362 (2009
18. Vogelgesang S, Warzok RW, Cascorbi I et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr. Alzheimer Res. 1(2), 121-125 (2004
19. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-b in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77(5), 715-723 (2010
20. Brenn A, Grube M, Peters M et al. b-Amyloid downregulates MDR1-P-glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int. J. Alzheimers Dis. 2011, 690121 (2011
21. Ishikawa T, Hirano H, Onishi Y, Sakurai A, Tarui S. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab. Pharmacokinet. 19(1), 1-14 (2004
22. Schaefer M, Roots I, Gerloff T. In vitro transport characteristics discriminate wild type MDR1 (ABCB1) from Ala893Ser and Ala893Thr polymorphisms. Eur. J. Clin. Pharmacol. 61(9), 718-718 (2005
23. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipoprotein E: high-avidity binding to b-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90(5), 1977-1981 (1993 (Pubitemid 23069980)
24. Elali A, Hermann DM. Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci. Signal. 3(142), (2010
25. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000 (Pubitemid 30183327)
26. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007 (Pubitemid 46175758)
27. Seedhouse CH, Grundy M, White P et al. Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin. Cancer Res. 13(23), 7059-7066 (2007 (Pubitemid 350276888)
28. Haenisch S, Cascorbi I. miRNAs as mediators of drug resistance. Epigenomics 4(4), 369-381 (2012
29. Mosyagin I, Runge U, Schroeder HW et al. Association of ABCB1 genetic variants 3435C>T and 2677G>T to ABCB1 mRNA and protein expression in brain tissue from refractory epilepsy patients. Epilepsia 49(9), 1555-1561 (2008
30. Frankfort SV, Doodeman VD, Bakker R et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol. Neurodegener. 1, 13 (2006
31. Kohen R, Shofer JB, Korvatska O et al. ABCB1 genotype and CSF b-amyloid in Alzheimer disease. J. Geriatr. Psychiatry Neurol. 24(2), 63-66 (2011
32. Innocenti F, Kroetz DL, Schuetz E et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol. 27(16), 2604-2614 (2009
33. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 11(1), 25-34 (2011
34. Grover S, Gourie-Devi M, Bala K, Sharma S, Kukreti R. Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on first-line antiepileptic drugs. Pharmacogenet. Genomics 22(6), 447-465 (2012
35. Qu J, Zhou BT, Yin JY et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci. Ther. 18(8), 647-651 (2012
36. Ufer M, von Stulpnagel C, Muhle H et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics (2011
37. Han JY, Lim HS, Yoo YK et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1), 138-147 (2007
38. Erdilyi DJ, Kamory E, Csokay B et al. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy. Pharmacogenomics J. 8(5), 321-327 (2008
39. Koldamova T, Lefterov IM, Staufenbiel M et al. The liver X receptor ligand T0901317 decreases amyloid b production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280(6), 4079-4088 (2005 (Pubitemid 40288571)
40. Wahrle SE, Jiang H, Parsadanian M et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118(2), 671-682 (2008 (Pubitemid 351206556)
41. Rodriguez-Rodriguez E, Mateo I, Infante J et al. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Res. 1280, 166-171 (2009
42. Katzov H, Chalmers K, Palmgren J et al. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to b-amyloid metabolism. Hum. Mutat. 23(4), 358-367 (2004 (Pubitemid 38461517)
43. Kolsch H, Lutjohann D, Jessen F et al. Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. Int. J. Mol. Med. 17(5), 791-794 (2006
44. Li Y, Tacey K, Doil L et al. Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci. Lett. 366(3), 268-271 (2004 (Pubitemid 39024279)
45. Loeb MB, Molloy DW, Smieja M et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J. Am. Geriatr. Soc. 52(3), 381-387 (2004 (Pubitemid 38339518)
46. Rautio J, Humphreys JE, Webster LO et al. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab. Dispos. 34(5), 786-792 (2006
47. Westphal K, Weinbrenner A, Zschiesche M et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 68(4), 345-355 (2000
48. Sherman BM, West JH, Korenman SG. The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women. J. Clin. Endocrinol. Metab. 42(4), 629-636 (1976
49. Tang MX, Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348(9025), 429-432 (1996 (Pubitemid 26267873)
50. Schmidt R, Kienbacher E, Benke T et al. Sex differences in Alzheimer's disease. Neuropsychiatry 22(1), 1-15 (2008
51. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC. Augmented senile plaque load in aged female b-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158(3), 1173-1177 (2001 (Pubitemid 32221809)
52. Brain-Net. www.brain-net.net